Introduction
============

Bacterial resistance to antibiotics certainly does not represent a novel event. Since the introduction of benzylpenicillins ([Figure 1.1](#f1-idr-1-027){ref-type="fig"}), it has been observed that given enough time, bacteria will develop resistance to virtually any antibiotic introduced into clinical practice ([Table 1](#t1-idr-1-027){ref-type="table"}). Currently, antibiotic resistance largely defines the epidemiology and pharmacologic therapy of infectious diseases. β-lactam resistant Gram-positive bacteria provide the best illustration of this phenomenon. The "persistent pathogen", *Staphylococcus aureus*, is even more formidable since it manifested resistance to methicillin and other semi-synthetic penicillins, giving rise to the acronym "MRSA" (methicillin resistant *S. aureus*) ([@b106-idr-1-027]). Presently, and perhaps in a more virulent fashion due to its association with Panton-Valentine leucocidin (PVL, an exotoxin active against neutrophils), MRSA has been implicated in a surge of community-acquired infections (CA-MRSA) that is reaching epidemic proportions ([@b139-idr-1-027]; [@b59-idr-1-027]; [@b142-idr-1-027]; [@b62-idr-1-027]). Unfortunately, the entire class of β-lactam antibiotics currently in use is ineffective for the treatment of methicillin-resistant *S. aureus* (MRSA) infections. By virtue of its unique mechanism of action on the cell wall, vancomycin ([Figure 1.5](#f1-idr-1-027){ref-type="fig"}), the preeminent glycopeptide, became the antibiotic of "last resort" against resistant Gram-positive bacteria. Unfortunately, *Enterococcus* spp. established itself in the 1990s as a "respected pathogen" in the nosocomial setting, more problematic than in the past because of its frequent resistance to vancomycin (vancomycin-resistant *Enterococcus*; VRE) ([@b82-idr-1-027]). This unwelcome development, together with the threat of the emergence of vancomycin-intermediate and -resistant *S. aureus* (VISA and VRSA) ([@b125-idr-1-027]), conspire to imperil the status of vancomycin as the "workhorse" antibiotic for the treatment of infections caused by Gram-positive bacteria.

Efforts to find solutions to the "Gram-positive problem" have been fruitful. In the past decade, we witnessed the introduction into contemporary practice of oxazolidinones (eg, linezolid \[[@b129-idr-1-027]\] [Figure 1.11](#f1-idr-1-027){ref-type="fig"}), cyclopeptides (eg, daptomycin \[[@b35-idr-1-027]\] [Figure 1.9](#f1-idr-1-027){ref-type="fig"}) and glycylcyclines (eg, tigecycline \[[@b7-idr-1-027]; [@b31-idr-1-027]\] [Figure 1.12](#f1-idr-1-027){ref-type="fig"}), new classes of antibiotics with in vitro and clinical activity against MRSA and VRE. Furthermore, the rational design of new drugs based on "old molecules", the discovery of agents with novel mechanisms of action, and the innovative application of the principles of pharmacokinetics (PK) and pharmacodynamics (PD) to improve the use of existent drugs, offer great promise. Thus, we are at an important time to review the new antibiotics and those that are in development which target resistant Gram-positive pathogens. This article will summarize: i) the new generation of antibiotics effective against Gram-positive bacteria based on the modification of the parent β-lactam and glycopeptide structures; ii) the insights gained from the use of vancomycin; iii) the experience accumulated with the introduction of recently developed classes of antibiotics in the clinical arena; and iv) novel compounds in development. We also offer a clinical perspective to these emerging issues as infectious disease physicians.

New β-lactams against MRSA
==========================

The construction of the peptidoglycan backbone of the Gram-positive bacterial cell wall requires the polymerization of a polysaccharide chain formed by discaccharide-pentapeptide monomers, with alternating *N*-acetylglucosamine (NAG) and *N*-acetylmuramic (NAM) acid moieties, and cross-linked by peptide bridges. Enzymes termed D-alanyl-D-alanine transpeptidases mediate this last key step in the process. β-lactam antibiotics inhibit these enzymes, known as penicillin binding proteins (PBPs), by covalently binding to their serine site ([@b68-idr-1-027]). Recent studies reveal that the bacterial peptidoglycan takes a helical shape with a defined periodicity ([@b76-idr-1-027]). These finding forms the basis of novel approaches to inhibiting cell wall synthesis in bacteria.

The identification in 1961 in England of a strain of *S. aureus* resistant to methicillin marked the prelude of the end of β-lactam therapy against this organism. This strain spread successfully and rapidly in hospitals around the world, carrying the *mecA* gene that codes for PBP2a, which has very low affinity to any of the existent β-lactams. MRSA has since become the nosocomial pathogen "par excellence"; now, almost five decades later, we are in the midst of an epidemic of CA-MRSA that is changing the landscape of antimicrobial therapy. Translation from the laboratory to the clinic of β-lactams with the capacity to bind to PBP2a has become a therapeutic imperative. The current generation of anti-MRSA β-lactams, once approved for use by regulatory authorities after their validation in clinical trials, will represent a major breakthrough ([@b92-idr-1-027]; [@b101-idr-1-027]).

The most advanced among these molecules is ceftobiprole ([Figure 1.3](#f1-idr-1-027){ref-type="fig"}) ([@b18-idr-1-027]). This "fifth generation" cephalosporin demonstrates potent binding to PBP2a in MRSA (including VISA and VRSA \[[@b12-idr-1-027]\]), as well as to PBP2x in a penicillin-resistant *Streptococcus pneumoniae* strain and to PBP2 and PBP3 in *Escherichia coli* and *Pseudomonas aeruginosa* ([@b25-idr-1-027]). Additionally, it has demonstrated activity similar to ampicillin against *Enterococcus faecalis*, including vancomycin-resistant and β-lactamase-producing isolates ([@b6-idr-1-027]); it is not active against *Enterococcus faecium* ([@b51-idr-1-027]) ([Table 2](#t2-idr-1-027){ref-type="table"}). Although ceftobiprole is resistant to inactivation by a broad range of β-lactamases, it is hydrolyzed by extended-spectrum β-lactamases (ESBLs) found in *Escherichia coli* and *Klebsiella* spp. rendering its activity against Gram-negative bacteria comparable with that of cefepime ([@b96-idr-1-027]). The typical minimum inhibitory concentration (MIC) of ceftobiprole against MRSA is 2 μg/ml, contrasted with an MIC of \>64 μg/ml for ceftriaxone. PK/PD studies in humans demonstrate that ceftobiprole has an elimination half-life of about 3 hours and predominantly urinary excretion ([@b83-idr-1-027]).

A phase 3 multi-centered, global, randomized, double-blind trial comparing the efficacy of ceftobiprole with that of vancomycin in patients with complicated skin and skin structure infections (CSSSI) caused by Gram-positive bacteria (MRSA, MSSA, *Staphylococcus epidermidis*, and β-hemolytic streptococci) showed that both drugs were equivalent. In this trial, 282 patients received ceftobiprole intravenously (IV) 500 mg every 12 h and were compared with 277 patients who received vancomycin 1 gram IV every 12 h. Cure rates for patients with MRSA infections were 91.8% (56/61) with ceftobiprole treatment and 90.0% (54/60) with vancomycin treatment ([@b88-idr-1-027]). A second clinical trial comparing ceftobiprole monotherapy versus treatment with vancomycin plus ceftazidime was also carried out, with important variations ([@b87-idr-1-027]). This design included patients with CSSSIs caused by Gram-negative bacteria (*E. coli*, *P. aeruginosa*, *Klebsiella pneumoniae*, *Proteus mirabilis*, *and Enterobacter cloacae*) in addition to Gram-positive bacteria. Thus, patients with diabetic foot infections could be included. A more frequent dosing scheme (ceftobiprole 500 mg IV every 8 hours), and a longer infusion period (120 minutes vs. 60 minutes) were used. These modifications derived from PK studies that demonstrated a higher probability of achieving bactericidal and bacteriostatic targets with this dose; an important caveat derived from this data is that bactericidal concentrations against AmpC producing *Enterobacteriaceae* were not achievable ([@b71-idr-1-027]). Clinical cure rates and microbiological outcomes were similar in both arms across the range of pathogens and CSSSIs. Of note, slightly worse outcomes (but similar in both arms) were observed in patients with diabetic foot infections and MRSA infections; the subgroup of patients infected with MRSA that expressed PVL had better outcomes when treated with ceftobiprole (although statistical significance was not reported). Importantly, adverse events were rare among ceftobiprole-treated patients in both trials; a prolonged infusion time of 120 minutes caused a lower incidence of nausea and vomiting. Clinical trials evaluating the utility of ceftobiprole in the treatment of community- and hospital-acquired pneumonia (CAP and HAP, respectively) are underway.

A second cephalosporin with affinity to PBP2a, ceftaroline ([Figure 1.4](#f1-idr-1-027){ref-type="fig"}), is also in development. It has demonstrated activity against MSSA, methicillin-resistant *S. epidermidis* and MRSA. When tested against a collection of CA-MRSA strains, the MIC~50~ and MIC~90~ were 0.5 μg/ml ([@b107-idr-1-027]). Ceftaroline is also active against strains of *S. pneumoniae* that are resistant to ceftriaxone, as well as *Hemophilus influenzae* and *Moraxella catharralis*. Similar to ceftobiprole, ceftaroline inhibited strains of both vancomycin-susceptible and -resistant *E. faecalis*, but was inactive against *E. faecium*. In contrast, its activity against Gram-negative bacteria is inferior to that of extended spectrum cephalosporins. Ceftaroline shows higher ranges of MICs against penicillinase-producing *E. coli* and *Klebsiella* spp. and *Enterobacter*, *Citrobacter* and *Serratia* spp. (0.12--1 μg/ml) than ceftriaxone, cefotaxime, ceftazidime, and cefepime. Ceftaroline is inactive against organisms producing ESBLs and AmpC β-lactamases; it is also inactive against anaerobes, *Acinetobacter* spp., and *P. aeruginosa* ([@b84-idr-1-027]).

A phase 2 clinical trial evaluated the safety and efficacy of ceftaroline in the treatment of CSSSI caused by aerobic Gram-positive bacteria, comparing it to "standard therapy" (vancomycin with and without aztreonam). The clinical cure rate was 96.7% for ceftaroline versus 88.9% for standard therapy, but this study was not powered for inferential statistical analysis ([@b137-idr-1-027]).

A great deal of optimism also accompanies the development of anti-MRSA carbapenems. These new compounds feature modifications to the carbapenem structure that have resulted in improved affinity for PBP2a, among other PBPs. In contrast to ceftobiprole and ceftaroline, these molecules are also stable against Class A and C β-lactamases and therefore retain activity against Gram-negative bacteria producing extended-spectrum and AmpC cephalosporinases, as well as activity against anaerobes. These products have not been the subject of clinical trials yet. Some of the strongest candidates for further clinical development include: i) ME1036, which demonstrates very high affinity to miscellaneous PBPs and is active *in vitro* against a broad collection of Gram-positive and Gram-negative isolates from the United States such as MRSA, penicillin-resistant *S. pneumoniae*, 3rd generation (extended-spectrum) cephalosporin-resistant *Enterobacteriacea* (ESBL and AmpC producing) and vancomycin-resistant *E. faecalis*, but not against vancomycin-resistant *E. faecium*; ii) PZ-601 (SMP-216601), which has been demonstrated *in vitro* activity against a similar collection of clinical strains from USA and Japan; iii) FSI-1297, also active *in vitro* against MRSA and vancomycin resistant *E. faecalis* (MIC = 1 μg/ml) but less potent against vancomycin resistant *E. faecium* (MIC = 8 μg/ml); iv) RO4908463 (CS-023), active against MRSA and *P. aeruginosa* (47th Interscience Conference on Antimicrob Agents Chemother (ICAAC), Abstracts E-280, F1-341, A-29, Chicago, 2007.)

New glycopeptides in clinical development
=========================================

Vancomycin ([Figure 1.5](#f1-idr-1-027){ref-type="fig"}) belongs to the class of glycopeptides, a family of antibiotics produced by a diverse group of Actinomycetes. Other well-known representatives of this class include teicoplanin, widely employed around the world but not approved for use in the United States, and avoparcin, formerly used in Europe in animal husbandry. The chemical moiety that glycopeptides share in common is a heptapeptide. The heptapeptide backbone forms a carboxylate binding pocket that joins by forming hydrogen bonds to D-alanyl-D-alanine (D-Ala-D-Ala) peptidyl residues of the disaccharide-pentapeptide monomers (composed of N-acetylmuramic acid and N-acetylglucosamine). This prevents the transpeptidation and transglycosilation reactions that the disaccharide-pentapeptide intermediates must undergo in order to polymerize and form the peptidoglycan cell wall. This ultimately leads to the inhibition of bacterial cell wall synthesis.

The best understood mechanisms of resistance against vancomycin is the elimination of the D-Ala-D-Ala binding target or the replacement of the terminal D-Ala by D-lactate (D-Lac) or D-serine (D-Ser), to which the heptapeptide cannot bind efficiently ([@b23-idr-1-027]). Even though this represents the change of a single moiety, the enzymatic machinery necessary to produce it depends on a complex mechanism which involves the acquisition and regulation of several genes (eg, *vanR*, *vanS*, *van H*, *vanA*, *vanX*, *vanY)* through mobile genetic elements or transposons. This results in the expression of different phenotypes of glycopeptide resistance, denominated as VanA, -B, -C, -D, -E, and -G. For example, VanA denotes vancomycin and teicoplanin resistance associated with transposon Tn*1546*, found mostly among *E. faecium* and *E. faecalis* and described in *S. aureus*. VanB is vancomycin resistant but teicoplanin susceptible, and is associated with transposons Tn*1547* and *1549*. VanC differs in that it is not associated with a mobile genetic element but is intrinsic to *Enterococcus gallinarum* and *casseliflavus*, and depends on a shift of D-Ala to D-Ser (as opposed to D-Lac). An additional mechanism of resistance, the overexpression of D- Ala residues that results in intermediate susceptibility to vancomycin, has been described in *S. aureus* (see below).

Despite sharing the same basic mechanism of action, the activity of glycopeptides against Gram-positive cocci is not homogeneous, probably explained by differences in their structure outside of the common heptapeptide moiety. These various structure -- activity relationships among glycopeptides were exploited to develop a new generation of lipoglycopeptides that are able to overcome resistance to vancomycin, among which dalbavancin ([Figure 1.6](#f1-idr-1-027){ref-type="fig"}), telavancin ([Figure 1.7](#f1-idr-1-027){ref-type="fig"}), and oritavancin ([Figure 1.8](#f1-idr-1-027){ref-type="fig"}) are the more advanced representatives. The enhanced antibacterial activities of these lipoglycopeptides may derive from the ability of a hydrophobic side chain to cause both dimerization and binding to bacterial membranes ([@b3-idr-1-027]). These cooperative interactions enhance binding at the traditional glycopeptide target. Additionally, the novel glycopeptides take advantage of alternative mechanisms of action; for instance, they may act by direct binding and inhibition of transglycosylation, inhibition of RNA and lipid synthesis or direct disruption of the membrane. The coexistence of multiple mechanisms of action in one drug results in increased activity as demonstrated by lower MICs, when compared against vancomycin ([Table 2](#t2-idr-1-027){ref-type="table"}). For example, the MIC of vancomycin against *S. pneumoniae* ranges from 0.25 to 2 μg/ml, whereas for the new glycopeptides it ranges from 0.002 to 0.12 μg/ml; the MIC for VanA and VanB *Enterococcus* spp. drops eight-fold ([@b91-idr-1-027]).

Oritavancin ([Figure 1.8](#f1-idr-1-027){ref-type="fig"}), the first of the novel lipoglycopeptides, illustrates this search for compounds with improved spectrum and PK/PD characteristics based upon the existing structures of vancomycin and teicoplanin. The addition of a clorphenylbenzyl side chain ([Figure 1](#f1-idr-1-027){ref-type="fig"}) permits the dimerization of oritavancin molecules and hydrophobic interactions with the bacterial membrane that facilitate binding to peptidoglycan residues, even D-Ala-D-Lac ([@b2-idr-1-027]; [@b3-idr-1-027]). Oritavancin demonstrates *in vitro* activity against *Enterococcus* spp., including VRE (VanA, VanB, and VanC), and *Streptococcus* (*S. pneumoniae*, *S. pyogenes*, *S. agalactiae*). It is also active against methicillin-susceptible *S. aureus* (MSSA) and MRSA, with MICs ranging between 1--4 μg/ml, making it less potent than other glycopeptides ([Table 2](#t2-idr-1-027){ref-type="table"}). Nevertheless, it is bactericidal against enterococci and staphylococci, unlike vancomycin ([@b67-idr-1-027]; [@b89-idr-1-027]). Animal models suggest its activity is concentration dependent but a study in humans indicated that percentage of time above MIC was an important parameter of successful therapy in patients with *S. aureus* bacteremia ([@b14-idr-1-027]; [@b9-idr-1-027]). Because of its prolonged half-life, once daily dosing is feasible. There are no published clinical data on the use of oritavancin, but it is in development for the treatment of CSSSI. Despite its promise, there has been a several year hiatus in the development of oritavancin.

Dalbavancin ([Figure 1.6](#f1-idr-1-027){ref-type="fig"}), derived from teicoplanin, is perhaps the most clinically advanced of the novel glycopeptides ([@b10-idr-1-027]). In addition to binding to the D-Ala-D-Ala terminals of the growing peptidoglycan chain, dalbavancin interacts with the bacterial cell membrane, conferring it potent *in vitro* activity against MSSA, MRSA, *S. pneumoniae*, and β-hemolytic streptococci ([@b53-idr-1-027]). Dalbavancin was equally potent against enterococci, including VRE but not VanA-resistant phenotypes ([@b52-idr-1-027]; [@b132-idr-1-027]). It is active against VRSA ([@b15-idr-1-027]) and miscellaneous Gram-positive anaerobes ([@b37-idr-1-027]). Its unique characteristic is that it is intensely protein-bound, leading to an extended half-life (mean 181 h), so that it can be dosed once weekly.

Phase 2 and phase 3 trials demonstrate equal effectiveness of dalbavancin in the treatment of CSSSI when compared with 14-day courses of vancomycin and linezolid, respectively ([@b49-idr-1-027]; [@b117-idr-1-027]). A phase 2 study of patients with staphylococcal (including MRSA) catheter-related bacteremias demonstrated superiority of dalbavancin administered twice daily for 14 days compared with vancomycin. Dalbavancin was administered at 1 gm on the first day and then 500 mg on the eighth day of treatment in all of these trials. This unusual dosing schedule makes it a very appealing compound for outpatient therapy. The concern is the potential occurrence of adverse effects, which logically would also be long lasting given the long-half life of the compound. The above-mentioned studies, however, suggest a very favorable safety profile.

Telavancin ([Figure 1.7](#f1-idr-1-027){ref-type="fig"}) is structurally similar to vancomycin. The modifications on the original glycopeptide, namely the alkylation of the vancosamine substituent with a hydrophobic moiety, result in a multifunctional mechanism of action. The side chain promotes interaction with the cell membrane, improving affinity for D-Ala-D-Ala and altering the bacterial cell membrane potential and permeability ([@b43-idr-1-027]). This results in greater bactericidal activity and potency against staphylococci and enterococci, even VISA, VRSA, and VRE with Van A phenotype ([Table 2](#t2-idr-1-027){ref-type="table"}). Similar to the other novel glycopeptides, telavancin has excellent in vitro activity against β-hemolytic streptococci and *S. pneumoniae* ([@b66-idr-1-027]; [@b22-idr-1-027]; [@b48-idr-1-027]). Additionally, when compared with vancomycin, telavancin has a longer half-life (up to 9 h) so that it can be given once a day ([@b118-idr-1-027]).

There are two published phase 2 clinical trials comparing telavancin (dosed at 7.5 mg/kg/day and 10 mg/kg/day, respectively) against standard therapy with a β-lactam or vancomycin for the treatment of CSSSI caused by Gram-positive bacteria. Overall, the outcomes were equivalent beween the two arms, except in the group with MRSA infection in which microbiological eradication and clinical cure appeared better in patients treated with telavancin ([@b134-idr-1-027], [@b133-idr-1-027]). Side effects consisted mostly of nausea and vomiting; these occurred with equal frequency in the comparator arm. Further studies are underway to evaluate the efficacy of telavancin in the treatment of pneumonia, which is supported by animal and preliminary human data ([@b38-idr-1-027]; [@b41-idr-1-027]).

A novel compound, TD-1792, is described as a heterodimer in which a cephalosporin moiety is covalently linked to vancomycin. TD-1792 therefore inhibits both key cell wall synthesis functions, transpeptidation and transglycosilation. It has demonstrated bactericidal activity against MRSA, with very low MICs (0.03 μg/ml). The administration of its individual components, the cephalosporin and vancomycin, by themselves or together (but not covalently linked) failed to achieve such good parameters of activity (47th ICAAC, Abstract F1-2110, Chicago IL, 2007). Its eventual use in the clinical arena depends on further development and clinical trials that support its efficacy.

Enduring utility of vancomycin against *S. aureus*
==================================================

There is an ongoing debate among clinicians regarding the continued utility of vancomycin for the treatment of infections caused by MRSA. Trusting more than 50 years of experience and an improved compound free of major toxicities, physicians rely heavily on vancomycin. Furthermore, vancomycin retains activity against the vast majority of *S. aureus* isolates. In contrast, many have long considered vancomycin a sub-optimal antibiotic, for instance when compared with β-lactams for the treatment of MSSA. There is fear that vancomycin may be reaching obsolescence given the emergence of resistance. As argued in the recent point-counterpoint arguments published in infectious diseases journals, there are many subtleties involved ([@b29-idr-1-027]; [@b78-idr-1-027]).

In contrast to *Enterococcus* spp., high-level resistance to vancomycin among *S. aureus* (MIC ≥ 16 μg/ml) has been reported only sporadically, amounting to seven cases ([@b122-idr-1-027]), all from the United States. Analysis of the index case of VRSA from Detroit, Michigan in 2002 identified the transfer of *vanA*, a vancomycin resistance determinant linked to Tn*1546*, from *E. faecalis* to *S. aureus*, a finding replicated in the subsequent six isolates ([@b20-idr-1-027]). Because the potential universal dissemination of VRSA has not materialized yet ([@b17-idr-1-027]), the more common and immediate threat may be VISA (also referred to as glycopeptide intermediate *S. aureus*; GISA). First identified in 1996 in Japan and 1997 in the United States, VISA strains are characterized by thicker extracellular matrixes due to the overproduction of D-Ala D-Ala or decreased turnover in the peptidoglycan wall that serve as a decoy target for vancomycin, resulting in MICs 4--8 μg/ml ([@b125-idr-1-027]). Additionally, there is concern about the phenomenon of heteroresistance to vancomycin in *S. aureus* (hVISA). Subpopulations (MIC \> 2 μg/ml) exist within cultures of the same strain of *S. aureus* that are susceptible to vancomycin (MIC ≤ 1 μg/ml). Growth medium containing vancomycin selects for these subpopulations.

The gradual loss of *S. aureus* susceptibility to vancomycin observed in a patient with MRSA endocarditis during unsuccessful treatment with vancomycin, is the origin of a remarkable collection of studies investigating VISA *in vivo* ([@b72-idr-1-027]; [@b85-idr-1-027]; [@b120-idr-1-027]; [@b121-idr-1-027]). Tomasz and his group demonstrated the evolution of vancomycin resistance in *S. aureus* (from an MIC of 1 and 2 μg/ml to 8 μg/ml) through whole-genome sequencing, identifying the key mutations differentiating isogenic strains with progressive increases in the MIC of vancomycin isolated from a single patient. Thirty-five mutations appeared sequentially during the course of treatment. Furthermore, resistance to rifampin resulted as well, after administration of only one dose of this antibiotic. More intriguing, a 100-fold increase in the MIC of daptomycin (0.01 to 1 μg/ml) was observed, even though that antibiotic was not used as treatment. The mutations associated with these phenotypes were also identified.

Sakoulas and colleagues revealed another important component that furthers our understanding of hVISA: the loss of function of the accessory gene regulator (*agr*) operon. Changes in this genetic element, identified as the group II polymorphism, may confer higher MICs of vancomycin to *S. aureus*. This polymorphism is present in isolates with VISA and hVISA phenotypes and may be associated with vancomycin failure ([@b112-idr-1-027], [@b111-idr-1-027], [@b113-idr-1-027]; [@b80-idr-1-027]).

The difficult detection of hVISA in the microbiology laboratory hinders the assessment of the epidemiological and clinical impact of this phenotype. The method of reference, population-analysis profile (PAP) testing, is laborious and resource intensive ([@b143-idr-1-027]). Perhaps the best screening test for hVISA is the Etest macromethod, in which a high inoculum of bacteria (McFarland of 2) is used against Etest strips of vancomycin and teicoplanin ([@b141-idr-1-027]). The clinical impact of hVISA remains unclear. A study from Australia identified five patients with bacteremia caused by hVISA (defined by PAP); they were more likely to have high infections with high inoculum of bacteria, treatment failure and low vancomycin levels. A second survey by the same group looked at the outcomes of 25 additional patients with infections caused by *S. aureus* with reduced susceptibility to vancomycin; they had serious infections ranging from endocarditis to osteomyelitis, received prolonged and ineffective courses of vancomycin and had been previously infected with MRSA. It is difficult to ascertain in both cases whether the detection of hVISA in these patients was a cause or an effect of the above-mentioned factors ([@b21-idr-1-027]; [@b46-idr-1-027]). [@b32-idr-1-027] reviewed the studies reporting the clinical outcome of infection with hVISA, and did not find a consistent negative impact but rather conflicting results.

In 2006 the Clinical Laboratory Standards Institute (CLSI) lowered the vancomycin MIC breakpoints for *S. aureus* (from ≤4 μg/ml to ≤2 μg/ml for "susceptible," from 8--16 μg/ml to 4--8 μg/ml for "intermediate," and from ≥32μg/ml to ≥16 μg/ml for "resistant") ([@b138-idr-1-027]). The rationale for this change was, among other considerations, to signal that strains with MICs close to 4 μg/ml (until then considered fully susceptible) are likely to be hVISA and therefore would go unrecognized by the microbiology laboratory and may be associated with vancomycin treatment failure. Moreover, there are reports of poor clinical outcomes associated with strains of *S. aureus* with MICs of 1--2 μg/ml, which is within the new susceptible range as determined by CLSI ([@b116-idr-1-027]; [@b114-idr-1-027]). The application of a logistic regression model to a database of patients from Barcelona with MRSA bacteremia yielded similar results ([@b126-idr-1-027]). Treatment with vancomycin in the instance of bacteremia caused by an isolate with a vancomycin MIC of 2 μg/ml -- as defined by Etest -- was a factor independently associated with mortality. The database did not permit to assess the effect of serum vancomycin concentrations on outcomes, although the dosing regimen used in these patients targeted trough levels above 10 μg/ml.

The investigation of PK/PD parameters of vancomycin may clarify the association between heteroresistance and response to therapy. Studies have determined that the ratio of the area under the concentration-time curve to the MIC (AUC/MIC) predicts the clinical response to vancomycin ([@b105-idr-1-027]). Furthermore, in pneumonia caused by MRSA, an AUC/MIC ≥400 is associated with a better clinical response ([@b79-idr-1-027]). In contrast, a retrospective study on the dosing levels of vancomycin on MRSA healthcare-associated pneumonia (HCAP) ([@b50-idr-1-027]), demonstrated that vancomycin trough concentrations were similar in patients who lived and in patients who died (13.6 and 13.9 μg/ml, respectively). The investigators did not explore if the vancomycin MICs of the infecting strain may have had an impact on clinical outcome. However, PK data from this study showed that in order to achieve the above mentioned satisfactory AUC/MIC ratio of \>400, both a high vancomycin trough concentration (approximately 20 μg/ml) and a low MIC of 0.5 μg/ml are required. Other investigators have shown that there may be an advantage in achieving vancomycin through concentrations \>15 μg/ml within the initial 24 hours of treatment, but only in cases in which the infection is caused by strains with an MIC \<2 μg/ml ([@b42-idr-1-027]). The American Thoracic Society guidelines for the treatment of HAP caused by MRSA recommend dosing vancomycin to achieve trough concentrations of 15--20 μg/ml ([@b1-idr-1-027]). This suggestion, however, does not derive from clinical studies evaluating the effect of vancomycin serum concentrations with respect to patient outcome and has to be balanced with a higher risk of adverse events in the form of renal dysfunction (47th ICAAC, Session 104, Paper K-1096, Chicago, IL). Recently, an *in vitro* pharmacodynamic model investigated different doses of vancomycin for the treatment of simulated moderate and high inoculum infections with hVISA. In cases of high inoculum infections, up to 10^5^ cfu/ml of hVISA organisms (with MICs 2- to 4- fold higher than at their baseline) remained after the administration of doses of vancomycin as high as 5 g every 12 hours. This data may explain why treatment of high-inoculum infections caused by hVISA with vancomycin often results in failure ([@b97-idr-1-027]).

How does one reconcile the above observations in order to choose the appropriate therapy against MRSA infections in the clinic? We support the opinion that it is necessary to determine an accurate MIC of vancomycin in the microbiology laboratory, ideally with Etest or a broth-based method, particularly in cases of MRSA infections with high organism loads (eg, pneumonia, endocarditis), in difficult to reach compartments (eye, brain, etc), and in infections requiring prolonged treatment (endovascular infections). It can then be determined whether a satisfactory AUC/MIC ratio is achievable with aggressive vancomycin dosing regimens or if the use of an alternative antibiotic is preferable, a decision that needs to be modulated by the clinical response. Other strategies have been considered plausible improvements upon the limited performance of vancomycin against serious MRSA infections. Combination therapy with vancomycin and other agents has been attempted. A natural candidate has been rifampin, which is extremely bactericidal against *S. aureus* even in the intracellular compartment. Unfortunately, vancomycin is not able to neutralize rifampin's notable proclivity to engender resistance ([@b124-idr-1-027]; [@b147-idr-1-027]). Continuous infusion therapy, although promising for other antimicrobials, did not demonstrate increased effectiveness in the case of vancomycin in a randomized, multi-center study ([@b146-idr-1-027]; [@b56-idr-1-027]). The prospective evaluation of the above described strategies and other considerations is essential to help define the continued utility of vancomycin, vis-à-vis newer antibiotics.

The experience with recently released antibiotics active against resistant Gram-positive cocci
==============================================================================================

The approval by the United States Food and Drug Administration (FDA) of linezolid, daptomycin, and tigecycline, each representative of a new class of antibiotics active against MRSA and enterococci offered welcome therapeutic alternatives to vancomycin. Linezolid, approved in 2000, and daptomycin, introduced in 2003, have emerged as the "antibiotics of last resort" for the treatment of infections caused by VRE. A newer addition, tigecycline, combines activity against *S. aureus* (including MRSA) and *Enterococcus* spp. with a broad spectrum of activity against Gram-negative and anerobic bacteria. The role of these three agents within the antibiotic armamentarium continues to evolve, shaped by their specific characteristics, the experiences of clinicians, and the performance of these drugs in clinical trials ([@b93-idr-1-027]; [@b77-idr-1-027]).

Linezolid ([Figure 1.11](#f1-idr-1-027){ref-type="fig"}) was the first oxazolidinone released. By acting on the 50S ribosomal subunit, specifically the peptidyl-transferase center, linezolid blocks the binding of tRNA, interferes with protein synthesis and inhibits bacterial cell growth ([@b65-idr-1-027]). Linezolid is bactericidal against streptococci but bacteriostatic against MRSA and VRE *in vitro*. In contrast, a study carried out in patients with diabetic foot infection caused by MRSA (some of them were additionally VISA or VRSA) demonstrated that serum can potentiate the antimicrobial effect of linezolid resulting in bactericidal activity ([@b128-idr-1-027]). Its near-complete oral bioavailability makes linezolid a tremendously attractive antibiotic for the treatment of suspected or confirmed MRSA infections. In addition, linezolid offers the opportunity to potentially lower costs that result from hospitalization ([@b73-idr-1-027]). These advantages should be balanced with a high cost as an oral agent, compared to generic alternatives widely used in the community. Patients on linezolid suffer from neurological (peripheral neuropathy and optic neuritis) and hematological (anemia, leukopenia and thrombocytopenia) side effects resulting from the inhibition of mitochondrial protein synthesis, as well as drug-drug interactions (serotonin re-uptake inhibitors) ([@b11-idr-1-027]). Furthermore, resistance stemming from single nucleotide changes in varying numbers of copies of the genes encoding 23S ribosomal RNA has emerged during the course of treatment ([@b75-idr-1-027]).

An open label, multi-center, randomized controlled trial demonstrated that linezolid was superior to vancomycin in achieving microbiological cure in the treatment of CSSSIs due to MRSA ([@b144-idr-1-027]). However, additional trials are needed to confirm this result and ascertain that clinical cure rates with linezolid exceed significantly those of vancomycin ([@b54-idr-1-027]). Similarly, there is an ongoing controversy regarding the superiority of linezolid for the treatment of HAP and ventilator-associated pneumonia (VAP) caused by MRSA. Although the initial phase 2 randomized controlled trials showed equivalence between linezolid and vancomycin, further analysis of the same data showed that there was an advantage in survival in patients treated with linezolid; of note, the serum concentrations of vancomycin in patients included in these trials were not reported ([@b103-idr-1-027]; [@b145-idr-1-027]). A recently published meta-analysis favored linezolid ([@b33-idr-1-027]), but appropriately designed and powered studies (phase 3 trials) are still needed to settle this question. Although it does not have FDA approval for the treatment of bloodstream infections, a pooled analysis of five randomized studies comparing linezolid versus vancomycin for the treatment of *S. aureus* bacteremia demonstrated "noninferior" outcomes associated with linezolid ([@b119-idr-1-027]). [@b130-idr-1-027] observed that linezolid (as well as clindamycin) suppressed the translation in *S. aureus* of genes coding for extracellular protein toxins (eg, PVL, alpha-hemolysin, and toxic shock syndrome toxin 1). This supports the notion that linezolid not only inhibits bacterial growth but may also modulate the expression of virulence. Clinicians need to be careful about inferring a clinical advantage from these experimental findings. Despite its utility, there are still many unanswered questions regarding the use of linezolid for its FDA-approved indications (the treatment of CSSSIs and HAP/VAP), as well as its role in the treatment of bacteremia and endocarditis ([@b33-idr-1-027]).

Daptomycin ([Figure 1.9](#f1-idr-1-027){ref-type="fig"}) is a cyclic lipopeptide antibiotic, unique in its class, with potent *in vitro* activity against Gram-positive bacteria, including MRSA and VRE. Its mechanism of action is unclear but it seems to involve depolarization of the bacterial membrane and efflux of potassium ions, leading to cell death ([@b127-idr-1-027]). It is extremely bactericidal, even in instances of high inoculum/stationary phase infections, as demonstrated in biofilm and endocarditis models ([@b99-idr-1-027]; [@b102-idr-1-027]). Even though it penetrates well into vascular structures and the urinary tract, daptomycin does not penetrate into the central nervous system and its use in the treatment of pneumonia is contra-indicated because it is inhibited by pulmonary surfactant ([@b123-idr-1-027]). It has been demonstrated to be safe, with only occasional elevations in creatine kinase observed ([@b57-idr-1-027]).

The FDA approved the use of daptomycin for the treatment of CSSSI (at 4 mg/kg/day), as well as *S. aureus* including MRSA- bacteremia and right sided endocarditis (at 6 mg/kg/day). An important randomized controlled clinical trial showed that daptomycin was not inferior to a β-lactam antibiotic or vancomycin for the treatment of patients with *S. aureus* bacteremia and right-sided endocarditis ([@b35-idr-1-027]). However, in this trial daptomycin was associated with a high rate of microbiologic failure. It was also concerning that reduced susceptibility to daptomycin emerged among *S. aureus* isolates. This resonates with the clinical finding mentioned above that daptomycin resistant *S. aureus* populations appear to be linked to reduced vancomycin susceptibility, a phenomenon that needs further elucidation ([@b100-idr-1-027]). The mechanism of resistance to daptomycin has not been fully explained, but there are specific mutations associated with nonsusceptible *S. aureus* strains ([@b13-idr-1-027]). Despite this, and because of its convenient once-a-day dosing, its bactericidal action, and its favorable safety profile, the role of daptomycin in the clinic is expanding (eg, into the treatment of bone and joint infections) ([@b63-idr-1-027]). Nevertheless, its superiority to vancomycin in the treatment of MRSA infections and its efficacy in the treatment of infections caused by VRE has yet to be prospectively demonstrated. Of note, it is significantly less potent against VRE than against MRSA or than other compounds ([Table 2](#t2-idr-1-027){ref-type="table"}).

Tigecycline ([Figure 1.12](#f1-idr-1-027){ref-type="fig"}) is the sole representative of the class of glycylcyclines ([@b98-idr-1-027]), defined by a glycylamido (*tert*-butyl) moiety attached to the original tetracycline molecule, making it impervious to the efflux pumps (eg, *tetA* and *tetB*) that normally extrude tetracyclines from the bacterial cell. It also avoids the ribosomal protection proteins (eg, *tet*(*O*)). Since it is a tetracycline, it also binds to the 30S ribosomal subunit blocking the entry of amino-acyl tRNA and ultimately inhibiting protein synthesis. It has a broad spectrum of activity that includes MRSA and enterococci (including VRE) and also enterobacteria and anaerobes. The adequate performance of tigecycline in clinical trials support its use in the treatment of polymicrobial CSSSI and intra-abdominal infections ([@b7-idr-1-027]; [@b31-idr-1-027]). Although it is known to be inactive against *Pseudomonas* and *Proteus* spp. ([@b27-idr-1-027]; [@b140-idr-1-027]), tigecycline held promise as a treatment against multidrug-resistant enterobacteria and *Acinetobacter* spp. However, the results of the clinical experiences in the treatment of Gram-negatives recently published are disappointing ([@b4-idr-1-027]; [@b86-idr-1-027]). Tigecycline remains an option against MRSA and enterococci CSSTI ([@b81-idr-1-027]).

Of note, tigecycline has excellent penetration into tissues. Experiments with radiolabeled antibiotic demonstrated the AUC value in spleen, liver, and kidney to be at least eight times higher than in plasma. Tissue exposure in lung was more than four times higher than in plasma, whereas in bone it was several hundred-fold higher. It appears that tigecycline is primarily the subject of biliary excretion. Approximately 30% of the tigecycline is excreted unchanged in the urine ([@b74-idr-1-027]). Despite the above data, trials involving urinary tract infections were abandoned ([@b69-idr-1-027]). Therefore, more studies are needed before tigecycline can be recommended for that indication ([@b24-idr-1-027]; [@b61-idr-1-027]). The profile of adverse effects with tigecycline is remarkable for nausea and vomiting in a large proportion of patients, as well as increases in the blood urea nitrogen (BUN) consistent with the catabolic effects of tetracyclines. It must be noted that the original tetracyclines (ie, minocycline and doxycycline) have re-emerged to play a major role in the therapy against MRSA, mostly in the treatment of uncomplicated skin and soft tissue infections and as adjuvants in chronic suppressive regimens ([@b104-idr-1-027]).

On the horizon
==============

Iclaprim ([Figure 1.13](#f1-idr-1-027){ref-type="fig"}), a novel compound, represents a departure from a preexisting class of antibiotics, dihydrofolate reductase (DHFR) inhibitors. The best representative of this class is the diaminopyrimidine trimethoprim (TMP), currently used in the clinic in combination with sulfamethoxazole (SMX). TMP/SMX largely retains activity against MRSA and is very often used in the treatment of uncomplicated skin and soft tissue infections. However, resistance to TMP does occur, resulting from a single amino acid change in the active site of *S. aureus* DHFR that prevents the formation of hydrogen bonds with TMP. Iclaprim, also a diaminopyrimidine, incorporates a cyclopropyl group that allows for the formation of hydrogen bonds even in TMP resistant *S. aureus* ([@b115-idr-1-027]; [@b39-idr-1-027]). Furthermore, iclaprim is as equally effective as TMP in inhibiting DHFR in *S. aureus* and *E. coli*, but is an order of magnitude more efficient against DHFR from *S. pneumoniae* and *Pneumocystis jiroveci*. This translates into activity against MRSA, VISA, and VRSA, and against multidrug-resistant *S. pneumoniae* (β-lactam, macrolide, quinolone and TMP resistant). Iclaprim, like TMP, has adequate enteral bioavailability ([@b60-idr-1-027]; [@b64-idr-1-027]) and its clinical development is followed with interest.

A second class of DHFR inhibitors currently under development is that of dihydrophthalazine antifolates. Three compounds, BAL-30543, BAL-30544, and BAL-30545, have demonstrated activiy against MSSA, MRSA, VISA, and VRSA, and TMP-resistant *S. aureus*, as well as MDR-resistant *S. pneumoniae*. Similar to other DHFR inhibitors, they can be administered enterally and parenterally with excellent bioavailability (47th ICAAC, Abstracts F1-934 and 935, Chicago IL, 2007).

RWJ 416457, a novel oxazolidinone with a pyrrolopyrazolyl substitution, has been tested *in vitro* against a variety of organisms, including MRSA and VRE. It generally had two- to fourfold lower MICs than those of linezolid against most pathogens tested ([@b34-idr-1-027]). Similarly, when tested against linezolid-resistant enterococci and *S. aureus* it demonstrated lower MICs than linezolid but only by a couple of dilutions, indicating that RWJ 416457 is susceptible to the same mechanism of resistance than linezolid, namely mutations in genes coding for the 23S rRNA ([@b70-idr-1-027]).

Friulimicin ([Figure 1.10](#f1-idr-1-027){ref-type="fig"}), the natural product of *Actinoplanes friulensis*, is structurally similar to daptomycin and therefore is classified as a cyclic lipopeptide. Their mechanism of action, however, seems to differ. Friulimicin prevents cell wall synthesis by forming a calcium dependent complex with the bacroprenol-phosphate carrier whereas daptomycin's putative mechanism of action is the formation of pores that leads to extrusion of potassium and cell death. In general, friulimicin has a similar bactericidal activity as daptomycin against MRSA, *S. pneumoniae* and VRE, but typically its MICs are one dilution higher. The exception is *Streptococcus pyogenes* for which friulimicin has a fourfold higher MIC (4--8 μg/ml). Despite sharing a similar structure, friulimicin does not demonstrate cross-resistance with daptomycin. Unlike daptomycin, it is not inhibited by pulmonary surfactant and it appeared effective in a murine *S. pneumoniae* pneumonia model, as well as in a *S. aureus* abscess model (47th ICAAC, Abstracts F1-1640, 1642, 1643, 1647, 1651, 1652, Chicago, IL, 2007).

Api-1252 exploits a novel mechanism of action, the inhibition of bacterial enoyl-acyl carrier protein (enoyl-ACP) reductase (FabI). This compound is in development for the treatment of staphylococcal infections. In preliminary trials, it demonstrated potent *in vitro* activity against clinical isolates of MRSA (MIC~90~, 0.015 μg/ml), as well as *Staphylococcus epidermidis* ([@b55-idr-1-027]).

CBR-2092 is a novel rifamycin-quinolone hybrid antibiotic in the preclinical stages of development for the treatment of MRSA. It has shown activity in animal models of endocarditis against quinolone resistant MRSA. (47th ICAAC, Abstract F1-2102 Chicago, IL, 2007).

Finally, in the field of topical antibiotics, retapamulin ([Figure 1.14](#f1-idr-1-027){ref-type="fig"}) received FDA approval for the treatment of impetigo. A semisynthetic pleuromutilin derivative, it is active against MRSA, as well as *Streptococcus* spp. It inhibits protein synthesis by binding to the 50S portion of the ribosome in a different fashion than other antibiotics (blocks peptidyl transferase activity, and partially inhibits the binding of the initiator tRNA substrate to the ribosomal P-site), explaining the lack of cross-resistance ([@b148-idr-1-027]; [@b19-idr-1-027]; [@b47-idr-1-027]; [@b90-idr-1-027]). Another promising class of topical agents is that of diphenyl-ureas, active against MRSA and *Streptococcus* spp. and effective in murine models studying MRSA skin infection and nasal colonization (47th ICAAC, Abstract F1-2094-2100 Chicago, IL, 2007).

Conclusion
==========

The immediate conclusion after reviewing close to twenty of the antibiotics that are already in use or are in development for the treatment of infections caused by resistant Gram-positive bacteria is that there are indeed many options. The state of the antibiotic pipeline for Gram-positive bacteria appears to be very healthy. This poses a stark contrast with the situation in the Gram-negative realm, where there are serious and widespread misgivings about the capacity and willingness of the pharmaceutical industry to continue to meet the medical needs posed by certain infectious pathogens ([@b136-idr-1-027]). The ever present need for new antimicrobials is made more poignant by the emergence of resistance, which either has already been described for many of the agents discussed ([Table 1](#t1-idr-1-027){ref-type="table"}) or is predictable and waiting around the corner.

It also seems that, despite or because of the many options available, defining the therapy of "choice" for serious Gram-positive bacterial infections has become more difficult than ever. This apparent paradox underscores the notion that the value of an antibiotic does not lie within its chemical structure but in the body of knowledge supporting its use. As illustrated in the above discussion on the continued utility of vancomycin, multiple considerations and points of view apply and there are no simple answers. We hope that similar discussions about the newer compounds can be made in the future, informed by sound microbiological, clinical, and epidemiological studies.

A single drug is not likely to dominate the future antibiotic landscape; different indications may call for different therapies, as suggested by the example of MRSA pneumonia and linezolid. Individual patient responses to antibiotics and the multiplicity of side effects will also be a consideration; pharmacogenomics will be a powerful tool to discern the best therapy for each patient ([@b26-idr-1-027]). The longevity and robustness of our new armamentarium against Gram-positive bacterial infections will be determined by factors specific to each drug, such as effectiveness, convenience, cost, and emergence of resistance, as much as by efforts in the general aspects of immunization, infection control, and antibiotic stewardship.
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Chemical structures of select antibiotics active against Gram-positive cocci.
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###### 

Timeline of introduction of antibiotics active against *Staphylococcus aureus*; first report of resistance and description of mechanism of resistance

  **Antibiotic**     **Introduction**   **Resistance reported**   **Mechanism of resistance**                                                              **References**
  ------------------ ------------------ ------------------------- ---------------------------------------------------------------------------------------- ------------------------------------
  **Penicillin**     1943               1945                      β-lactamase                                                                              [@b28-idr-1-027]
  **Methicillin**    1959               1961                      Penicillin binding protein (PBP) 2a                                                      [@b8-idr-1-027]
  **Tetracycline**   1950               1955                      Efflux pumps (*tetK* and *tetL*) and ribosomal protection proteins (*tetM* and *tetO*)   [@b16-idr-1-027]
  **Vancomycin**     1956               1997/2002                 Abundance of D-alanyl D-alanine/shift to D-alanyl D-lactate                              [@b44-idr-1-027]; [@b20-idr-1-027]
  **Trimethoprim**   1965               1986                      Mutation in dihydrofolate reductase                                                      [@b5-idr-1-027]
  **Linezolid**      2000               2002                      Mutations in 23S ribosomal RNA                                                           [@b94-idr-1-027]
  **Daptomycin**     2003               2005                      Mutations in *mprF*, *rpoB*, and *rpoC* (unclear).                                       [@b40-idr-1-027]
  **Tigecycline**    2005               NR                        NR                                                                                       

**Abbreviation:** NR, not reported.

###### 

Activity of different antibiotics against selected Gram-positive bacteria

  **Antibiotic**     **MSSA**   **MRSA**   **VRSA**   **VRE**   **References**                 
  ------------------ ---------- ---------- ---------- --------- ---------------- ------ ------ -------------------------------------------------------------------------
  **Vancomycin**     1          1          1          1         32--1024         \>64   \>64   [@b149-idr-1-027]; [@b109-idr-1-027]; [@b122-idr-1-027]
  **Linezolid**      2          2          2          2         2--4             1      2      [@b30-idr-1-027]; [@b109-idr-1-027]; [@b122-idr-1-027]
  **Daptomycin**     0.25       0.5        0.25       0.5       ≤0.5--2          2      4      [@b110-idr-1-027], [@b109-idr-1-027]; [@b122-idr-1-027]
  **Tigecycline**    0.12       0.25       0.12       0.25      0.12             0.03   0.06   [@b15-idr-1-027]; [@b45-idr-1-027]; [@b36-idr-1-027]
  **Ceftobiprole**   0.25       0.5        1          2         1                4      8      [@b135-idr-1-027]; [@b15-idr-1-027]; [@b51-idr-1-027]; [@b95-idr-1-027]
  **Ceftaroline**    0.25       0.25       1          2         Not reported     16     \>32   [@b108-idr-1-027]
  **Oritavancin**    1          2          1          2         0.25^b^          1      2      [@b149-idr-1-027]; [@b15-idr-1-027]
  **Dalbavancin**    0.06       0.06       0.06       0.06      0.5^b^           4      32     [@b15-idr-1-027]; [@b131-idr-1-027]; [@b53-idr-1-027]
  **Telavancin**     0.5        0.5        0.25       0.5       2--4^c^          2      4      [@b58-idr-1-027]; [@b66-idr-1-027]

**Abbreviations:** MSSA, methicillin-susceptible *Staphylococcus aureus*; MRSA, methicillin-resistant *S. aureus*; VRSA, vancomycin-resistant *S. aureus*; VRE, vancomycin-resistant *Enterococcus*; MIC~50~, minimal inhibitory concentration for 50% of tested strains; MIC~90~, minimal inhibitory concentration for 90% of tested strains; MIC, minimal inhibitory concentration (μg/ml).
